GET DAILY SIGNALSWhy Is Capricor Therapeutics (CAPR) Stock Up +14.77% Today?
Key Takeaways
- Shares of CAPR climbed roughly 14.77% in today's session, trading near $10.18 versus a prior close of $8.87.
- The rally is being driven by renewed optimism ahead of the FDA's November 22 decision deadline for deramiocel, the company's lead Duchenne muscular dystrophy (DMD) therapy.
- Management reaffirmed confidence that its Biologics License Application is in the final stages of regulatory review.
- Positive sentiment was reinforced by an American Heart Association award recognizing HOPE-3 cardiac data, plus highly bullish retail positioning.
- The move follows a wider third-quarter loss, underscoring how much the stock is now trading on the binary FDA decision rather than near-term financials.
- Traders are watching the November 22 PDUFA date as the primary event risk.
- For more detail on valuation and technicals, explore Price Targets, Earnings, and Forecast.
- Discover the strongest-performing AI trading strategies currently covering this and other tickers on Trending AI Robots.
Opening Summary
Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases, saw its stock surge more than 14% in today's trading. Shares were changing hands around $10.18, up from the previous session's close of $8.87, a gain of approximately 14.77%. The advance extends a sharp rebound from Tuesday's after-hours move, as investors reposition ahead of a pivotal regulatory decision on deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy.
FDA Decision Looms as the Central Catalyst
The dominant driver behind the stock's rally is the approaching U.S. Food and Drug Administration action date of November 22 for deramiocel. Management told analysts that its Biologics License Application is in the final stages of review and that the company has submitted all information requested by the agency. CEO Linda Marbán struck a confident tone, emphasizing that the HOPE-3 trial met its primary efficacy endpoint with a statistically significant improvement in upper-limb function versus placebo.
That confidence is meaningful for investors because the asset has faced a turbulent regulatory path. The company's original cardiomyopathy-focused application was rejected in 2025, and an advisory committee later voted against the effectiveness evidence for that indication. Capricor subsequently refiled with a narrower indication focused on preserving upper-limb function, a population for which no therapy is specifically approved. This reframing has become the foundation of the current bullish thesis.
Positive Data Recognition Bolsters Sentiment
Adding momentum, cardiac results from the HOPE-3 late-stage trial recently received the Outstanding Research Award in Pediatric Cardiology at the American Heart Association Scientific Sessions. The recognition highlighted potential benefits on heart function and scarring, an area of high unmet need given that cardiomyopathy is a leading cause of death in DMD patients. While the cardiac endpoint did not reach statistical significance overall, the broader validation of the data set has reinforced investor confidence in the program's clinical foundation.
Earnings Report Underscores Binary Risk
The stock's advance comes despite a wider third-quarter loss. Capricor reported a net loss of $42.7 million, or $0.73 per share, versus a loss of $24.6 million, or $0.54 per share, a year earlier, with operating expenses rising on pre-commercial activities and manufacturing scale-up. The company generated no revenue in the quarter and cut roughly 10% of its workforce to align spending with the regulatory timeline. Cash and marketable securities totaled approximately $198.5 million as of September 30, which management said is sufficient to fund operations for at least 12 months.
The fact that shares rallied despite a wider loss illustrates the market's focus: the investment case now hinges almost entirely on the FDA's verdict, with financial results treated as secondary.
Market Context and Trading Activity
Trading activity reflected elevated conviction, with the stock rebounding sharply from a down regular session on Tuesday as sentiment turned bullish following the earnings call. Retail sentiment metrics pointed to extreme bullishness with a surge in message volume, while sell-side commentary has leaned positive ahead of the decision. The move diverged from the broader market, highlighting that this is a company-specific, catalyst-driven repricing rather than a sector-wide rotation in biotechnology.
What Comes Next for CAPR
The November 22 PDUFA date is the defining event for CAPR. An approval would open the company's first commercial revenue stream and validate its manufacturing readiness, while a rejection would reignite the sharp downside the stock has experienced through 2026. Investors are also monitoring the ongoing arbitration with distribution partner NS Pharma and the company's slower progress on its other pipeline programs. Given the binary nature of the decision, volatility is likely to remain elevated through the announcement, and positioning carries meaningful risk in both directions.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. While Tickeron offers hundreds of bots covering thousands of tickers, only the strongest performers under current market conditions are featured here. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a view into which automated approaches are currently generating the most consistent results. Explore the page to see which strategies are leading today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR in upward trend: price rose above 50-day moving average on November 03, 2026
CAPR moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CAPR as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 26 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for CAPR crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.498). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
Advertisement